Immunovant Inc (IMVT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 03/31
(Values in U.S. thousands)
| 06-2026 | 03-2026 | 12-2025 | 09-2025 | 06-2025 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -153,224 | -505,606 | -357,750 | -247,115 | -120,613 |
| Depreciation Amortization | 92 | 409 | 313 | 212 | 107 |
| Accounts receivable | 436 | 986 | 423 | 104 | 129 |
| Accounts payable and accrued liabilities | 2,597 | -10,350 | -8,903 | -10,466 | -9,401 |
| Other Working Capital | 14,926 | 42,064 | 530 | -4,939 | -15,439 |
| Other Operating Activity | 10,768 | 65,187 | 53,136 | 42,278 | 27,806 |
| Operating Cash Flow | $-124,405 | $-407,310 | $-312,251 | $-219,926 | $-117,411 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | N/A | -8 | N/A | N/A | N/A |
| Investing Cash Flow | $N/A | $-8 | $N/A | $N/A | $N/A |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 20,097 | 596,260 | 592,702 | 27,513 | 2,918 |
| Other Financing Activity | 0 | -504 | -586 | 0 | 0 |
| Financing Cash Flow | $20,097 | $595,756 | $592,116 | $27,513 | $2,918 |
| Exchange Rate Effect | -4 | -299 | 689 | 312 | -566 |
| Beginning Cash Position | 902,110 | 713,971 | 713,971 | 713,971 | 713,971 |
| End Cash Position | 797,798 | 902,110 | 994,525 | 521,870 | 598,912 |
| Net Cash Flow | $-104,312 | $188,139 | $280,554 | $-192,101 | $-115,059 |
| Free Cash Flow | |||||
| Operating Cash Flow | -124,405 | -407,310 | -312,251 | -219,926 | -117,411 |
| Capital Expenditure | N/A | -8 | N/A | N/A | N/A |
| Free Cash Flow | -124,405 | -407,318 | -312,251 | -219,926 | -117,411 |